186 related articles for article (PubMed ID: 30102771)
1. Rapid identification of antimicrometastases drugs using integrated model systems with two dimensional monolayer, three dimensional spheroids, and zebrafish xenotransplantation tumors.
Fu A; Peh YM; Ngan W; Wei N; Luo KQ
Biotechnol Bioeng; 2018 Nov; 115(11):2828-2843. PubMed ID: 30102771
[TBL] [Abstract][Full Text] [Related]
2. [Effects of PD98059 and LY294002 on subcutaneous xenograft of human endometrial carcinoma in nude mice].
Guo RX; Zhang RF; Wang XY; Shi HR; Qiao YH
Zhonghua Fu Chan Ke Za Zhi; 2011 Jun; 46(6):446-52. PubMed ID: 21781587
[TBL] [Abstract][Full Text] [Related]
3. Application of a fluorescence resonance energy transfer (FRET)-based biosensor for detection of drug-induced apoptosis in a 3D breast tumor model.
Anand P; Fu A; Teoh SH; Luo KQ
Biotechnol Bioeng; 2015 Aug; 112(8):1673-82. PubMed ID: 25728592
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Xie X; Tang B; Zhou J; Gao Q; Zhang P
Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
Urol Int; 2011; 87(1):105-13. PubMed ID: 21597260
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
Urol Int; 2011; 86(3):346-54. PubMed ID: 21273759
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
9. Improving zebrafish embryo xenotransplantation conditions by increasing incubation temperature and establishing a proliferation index with ZFtool.
Cabezas-Sainz P; Guerra-Varela J; Carreira MJ; Mariscal J; Roel M; Rubiolo JA; Sciara AA; Abal M; Botana LM; López R; Sánchez L
BMC Cancer; 2018 Jan; 18(1):3. PubMed ID: 29291719
[TBL] [Abstract][Full Text] [Related]
10. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis.
Harfouche R; Basu S; Soni S; Hentschel DM; Mashelkar RA; Sengupta S
Angiogenesis; 2009; 12(4):325-38. PubMed ID: 19685150
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
Furuya F; Lu C; Willingham MC; Cheng SY
Carcinogenesis; 2007 Dec; 28(12):2451-8. PubMed ID: 17660507
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
[TBL] [Abstract][Full Text] [Related]
14. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.
Yaguchi S; Fukui Y; Koshimizu I; Yoshimi H; Matsuno T; Gouda H; Hirono S; Yamazaki K; Yamori T
J Natl Cancer Inst; 2006 Apr; 98(8):545-56. PubMed ID: 16622124
[TBL] [Abstract][Full Text] [Related]
16. Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas.
Kim S; Kang J; Qiao J; Thomas RP; Evers BM; Chung DH
J Pediatr Surg; 2004 Apr; 39(4):516-21. PubMed ID: 15065019
[TBL] [Abstract][Full Text] [Related]
17. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric Analysis of Oncology Drug Screening with Aqueous Two-Phase Tumor Spheroids.
Shahi Thakuri P; Ham SL; Luker GD; Tavana H
Mol Pharm; 2016 Nov; 13(11):3724-3735. PubMed ID: 27653969
[TBL] [Abstract][Full Text] [Related]
19. VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.
Shao Z; Bao Q; Jiang F; Qian H; Fang Q; Hu X
PLoS One; 2015; 10(7):e0132655. PubMed ID: 26204252
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
